2022 FARE IMPACT REPORT
From the CEO

Overview of 2022

Raising Awareness. Leading the Food Allergy Community.

Investing in the Future. Fighting for a Cure.


LET’S GET LOUD! The Importance of Advocacy

Expanding Access. Addressing Inequities.

Giving for the Future of Food Allergy

2022 Donors

Board Members

Leaders

Food Allergy Research & Education (FARE) rose to the challenge of 2022 as the world began to emerge from a devastating pandemic and life returned to a new normal. Pride in all FARE’s accomplishments in 2022 is only exceeded by gratitude to all those whose passion and dedication to the cause of food allergy is making an impact.

FARE’s work over the past year has been exemplary and we are quickly moving toward our goals of elevating food allergies as a tier one disease and bringing us closer to solutions for all. This work could not have been possible without the leadership and commitment of FARE’s Boards, the support of generous donors and partners, and the advocacy of the food allergy community—whether through legislative action, media interaction and outreach, or expanded educational efforts. These contributions, whether in-person, in-kind, or in partnership, help advance the cause of food allergy and drive options to those most impacted by this condition.

On behalf of the FARE team, we present the 2022 Impact Report highlighting FARE’s impressive successes and looking positively to the future. There are also several links to compelling personal stories throughout the digital version of this report as we put a face on the critical work we do.

We are proud, we are grateful, and we are committed. Thank you to all those who support and fight for the lives of those impacted by food allergy.

Sung Poblete, RN, PhD
CEO
In 2022, FARE’s tenth anniversary year, the organization experienced growth, expansion and positive change. With a shift in leadership including stellar interim service by Dr. Bruce Roberts, FARE named a permanent CEO in May welcoming Sung Poblete, RN, PhD to the role. The ensuing months brought new vision, direction, and focus to FARE including a recommitment to FARE’s overall mission: to improve the quality of life and health of those with food allergies through transformative research, education, and advocacy.

As the nation’s leading non-profit engaged in food allergy advocacy as well as the largest private funder of food allergy research, FARE’s innovative education, advocacy, and research initiatives are transforming the future of food allergy through new and improved treatments and prevention strategies, effective policies and legislation, and novel approaches to managing the disease.

In order to best meet the needs of the food allergy community, a streamlined, integrated approach to FARE’s organizational structure has been established, recognizing the core competencies—or Pillars—of research, education and advocacy that serve as the foundation for all activities. Supporting these efforts is a commitment to, and focus on, health equity—an underlying principle that is also a common thread throughout the entire organization. This pillar approach has already proven successful at driving new innovations, partnerships, educational opportunities and outreach to all those impacted by food allergy.

Key accomplishments for 2022 outlined in this Impact Report include:

- The research pillar remaining laser focused on finding comprehensive treatment options for families, preventing the rise of food allergies, and replacing the oral food challenge with a novel diagnostic.
- The advocacy pillar passing new state laws, increasing national appropriations funding, and exponentially increasing FARE’s advocacy network.
- The education pillar hosting a highly visible and impactful FARE Summit as well as Food Service Summit, while expanding educational opportunities through support groups and FARE’s highly visible Teen Advisory Group (TAG).
- Health equity initiatives continuing at the core of FARE’s work promoting diversity, equity, inclusion and access to care through impactful efforts such as the Community Access Program.

The many accomplishments of 2022 could not have been possible without strong leadership, committed advocates and staff, generous donors and corporate partners, and a host of passionate and driven members of the food allergy community. FARE is grateful to members of the Board of Directors, Board of Governors, Board of National Ambassadors, Rising Leaders, and all those impacted by food allergy who are working in lock-step to raise awareness of food allergy as a life-threatening and tier one disease, while also driving innovation in the search for a cure. With this drive and determination, the eradication of food allergies can be a reality.

MISSION CRITICAL PRIORITIES

VISION
A FUTURE FREE FROM FOOD ALLERGIES

MISSION
TO IMPROVE THE LIFE AND HEALTH OF THOSE WITH FOOD ALLERGIES THROUGH TRANSFORMATIVE RESEARCH, EDUCATION, AND ADVOCACY

GOALS
1. ACCELERATE THE PACE OF INNOVATIONS TO PREVENT, DIAGNOSE, AND TREAT FOOD ALLERGIES
2. EMPOWER FOOD ALLERGIC INDIVIDUALS TO CONFIDENTLY MANAGE THEIR CONDITION

MISSION-CRITICAL PRIORITIES

VISION
A FUTURE FREE FROM FOOD ALLERGIES

MISSION
TO IMPROVE THE LIFE AND HEALTH OF THOSE WITH FOOD ALLERGIES THROUGH TRANSFORMATIVE RESEARCH, EDUCATION, AND ADVOCACY

GOALS
1. ACCELERATE THE PACE OF INNOVATIONS TO PREVENT, DIAGNOSE, AND TREAT FOOD ALLERGIES
2. EMPOWER FOOD ALLERGIC INDIVIDUALS TO CONFIDENTLY MANAGE THEIR CONDITION
RAISING AWARENESS, LEADING THE FOOD ALLERGY COMMUNITY.

Through a centralized strategic messaging process, FARE has been working to “speak with one voice” by developing and implementing a strategy to include:

1. Positioning FARE as the **leading authority** in the food allergy space
2. Transforming awareness, education, advocacy, and fundraising through a focus on research
3. Educating the food allergy community, policymakers, and the public to establish a baseline understanding of the disease.

The FARE brand achieved a higher level of awareness in 2022, through coordinated outreach efforts led and supported in part by communications and marketing. Notably, there was an increase of over 70,000 individuals that would recommend FARE to others, outperforming other non-profit recognition statistics. Activities such as The Teal Pumpkin Project, Food Allergy Awareness Week, 10th Anniversary, Courage at Congress, Community Access Program events and the Food Allergy Summit; legislative wins (such as Zacky’s Bill and others); and food allergy issue thought leadership (such as epinephrine access), were instrumental ingredients in elevating the FARE brand and profile to key audiences and the general public through strategic marketing, traditional and social media engagement, influencer engagement and notable corporate partnerships like CVS.

FARE’s compelling storytelling continues to grow in engagement, awareness, and impressions, with programs like Sunday Stories bringing the realities and challenges of living with food allergy to the general public. With continued investment in engaging initiatives to increase awareness and provide resources to food allergy patients and their families, FARE engaged audiences through online and traditional news outlets, social channels, and digital platforms—with impactful results. By elevating the FARE brand, we have a higher level of interest in, and support of, the overall FARE mission.

### AWARENESS IMPACT HIGHLIGHTS BY THE NUMBERS

#### DATABASE
- +18.99% increase to the database

#### MEDIA
- **Social Media**
  - Impressions: +39M (+27.8%)
  - Engagement: +4M (+300%)
  - Audience: +73%
  - Video views: +10M (+130%)

- **Traditional Media**
  - 16.1 B Total Readership
  - $30.27 M Ad Equivalency

- **Social Channels**
  - FB Followers: +200K
  - IG followers: +43K
  - Twitter: +24K
  - LinkedIn: +6K

#### CAMPAIGNS
- **The Teal Pumpkin Project**
  - Awareness & lead generation campaign
  - +16K map pins
  - 278,760 TPP Page views
  - +14M Impressions
  - Earned media
  - TPP Total audience reached: 397,111,710
  - TPP Total value of coverage: $13,272,588

- **Thanksgiving Cookbook**
  - Lead generation campaign
  - 2.8M Impressions
  - 1.8M vid views
  - 2417 downloads

---

FARE WEBSITE
- +3M pageviews (+3.2%)
- +1.6M unique website visitors (+3.1%)
NEW pediatrics guidelines have slowed increase in food allergy anaphylaxis rate

By Richard Galvin
Perspective From Bruce Roberts, PhD

**Health Digest**

**Everything You Need To Know About Nut Allergies**

Story by Ariane Lang • Aug 11, 2022

**Yahoo!**

**Parade**

The Meaning Behind 13 Different Halloween Pumpkin Colors—Decoded

Stephanie Osmanski
August 30, 2022 • York Times

**Progressive Grocer**

Fare, Sifter Team on Grocery Shopping Tech for Food Allergy Community

Technology
Health & Wellness

**BuzzFeed News**

Chick-Fil-A And Other Restaurants Added Sesame To Their Food And People With Sesame Allergies Are Pissed

People are concerned that restaurants and food manufacturers may be adding sesame to products in response to a law that was passed to make it easier for those with allergies to identify the ingredient.

**NPR**

**Children's Health**

How teal pumpkins make Halloween less scary for trick-or-treaters with allergies

October 31, 2022 • 4:32 PM ET

Heard on All Things Considered

5-Minute Listen
As the largest private funder of food allergy research, FARE is powering breakthroughs to improve patient care and reverse the rising prevalence of this life-changing and potentially life-threatening disease. FARE engages in all areas of food allergy research, from benchtop discoveries in the laboratory to translational investigations in the clinic that can offer hope to patients as we work toward realizing a future free from food allergies.

Throughout 2022, FARE leveraged the research capabilities that we developed through the expansion of the FARE Clinical Network, a nationwide coalition of top food allergy centers led and coordinated by FARE, and the establishment of the FARE Biobank and Biomarker Discovery Center, a central resource for biospecimens, biomarker discovery and translational research; the FARE Data Coordination Center, which supports critical FARE Clinical Network activities for the design, development, execution, monitoring, and analyses of translational research; and the FARE Patient Registry, which collects patient-reported outcomes data offering insights into the patient journey and burden of disease.

FARE’s 2022 initiatives supported investigations to accelerate advances in food allergy diagnosis, treatment, and prevention, as well as to uncover molecular and cellular mechanisms responsible for food allergy. In addition to collaborations within the FARE Clinical Network and with organizations who share our research goals, FARE has partnered with pharmaceutical and biotech companies to facilitate the advancement of their candidate biologics and immunotherapy treatments.

FARE Innovation Award Diagnostic Challenge

In October 2022, FARE announced that a team headed by Beckman Coulter Life Sciences won the first stage of the FARE Innovation Award Diagnostic Challenge. This $1,000,000 prize will help foster the development of new, accurate, accessible testing methods for the diagnosis of food allergies and thereby minimize the use of oral food challenges.

The prize-winning proposal is a next-generation basophil activation test—a cell function assay using whole blood that is currently employed in research settings. Beckman Colter investigators have devised a way to stabilize blood samples, so analysis does not need to occur within hours of sample acquisition. This development will enable the analysis of samples derived from multiple sites including the FARE Biobank and Biomarker Discovery Center at Cincinnati Children’s Hospital Medical Center. Additional awards for diagnostic innovation are planned for 2023.

Clinical Trials

We are excited by progress made in FARE-supported clinical trials to improve strategies for food allergy prevention and treatment. In the SEED trial to prevent food allergy through early dietary introduction of multiple food allergens, researchers have enrolled more than 120 infants who were recruited at six sites in the Chicago area.

Another FARE-supported trial, COMBINE, is exploring the safety and effectiveness of multi-allergen oral immunotherapy augmented by two biologic drugs, dupilumab and omalizumab, with the goal of patients attaining long-term desensitization to food allergens. More than 80 subjects have been enrolled in the trial at three FARE Clinical Network sites in California, leaving about 30 additional subjects to be added. Forty-three subjects have completed the study, and results are anticipated in 2024.

FARE is also collaborating with companies engaged in biotechnology research and drug development related to food allergy, with FARE and the FARE Clinical Network facilitating patient recruitment and clinical trials. FARE Clinical Network institutions are presently engaged in all phases of clinical research with multiple industry partners to evaluate allergen-based immunotherapies, biologic drugs and probiotic interventions.
**Basic Research Exploring Neuroimmune Communications in Food Allergy**

FARE and the Food Allergy Science Initiative (FASI) are entering the third and final year of a multi-million-dollar collaboration supporting research to elucidate the role of the enteric nervous system in food allergy. Understanding how the interplay of the brain, gut and immune system impact mouse models of food allergy can ultimately reveal molecules to target and pathways to disrupt in the treatment for human patients. By linking fundamental studies like this one to infrastructure for translational research and industry partners engaged in drug development, FARE can help promising benchtop discoveries move forward.

**Collection of Biobank Specimens**

The FARE Biobank and Biomarker Discovery Center at Cincinnati Children’s Hospital Medical Center and the FARE Data Coordination Center at Children’s Hospital of Philadelphia are collaborating with other FARE Clinical Network institutions on a multi-site study to collect 1,000 biospecimens from food allergy patients and healthy volunteers for future food allergy research. Extensive metadata associated with these specimens, including clinical histories and results from oral food challenges, skin prick tests, and serum specific IgE tests, will aid investigators in characterizing the food-allergic population and identifying distinct subtypes and disease mechanisms within food allergy. Sixty-nine specimens had been collected as of December 2022.

**Annual Research Retreat and First Food Allergy Clinical Development Meeting**

Featuring 28 speakers from academia, industry, the public sector and patient advocacy, FARE’s tenth annual Contains: Courage Research Retreat took place October 11-12. Four hundred participants took part in the virtual conference, which included 13 hours of keynotes, presentations, and Q&A sessions highlighting advances in food allergy biology, patient data, diagnosis, monitoring, treatment, and prevention.

To further foster collaboration and information sharing among industry leaders in biotech, pharma, and consumer packaged goods who are innovating to treat and prevent food allergy and other atopic diseases, FARE complemented the online Research Retreat by hosting Advances in Food Allergy Clinical Development, an in-person gathering held October 14, at the National Press Club in Washington, DC. More than 50 participants attended the meeting, including representatives from the U.S. Food and Drug Administration and more than 20 companies.
FARE is proud to provide access to training and resources that help make the world a safer and more inclusive place for those managing food allergies. Through novel and extensive programs and activities such as the Food Allergy Academy, the FARECheck program, and the Teen Advisory Group (TAG), FARE addresses the real-life issues of living with life-threatening food allergies; and provides guidance, support, and information to all those impacted by this condition.

New educational programs and achievements in 2022 were numerous and impactful.

FARE’s Food Allergy Academy offers live and on-demand education content for the food allergy community. Through its new learning management system, the Academy has been able to deliver expanded online courses, interactive trainings, and educational content. The top training module of 2022 was the revised and updated Save a Life: Recognizing and Responding to Anaphylaxis program, which received 74,269 views and was also posted to YouTube for ease of access. Top webinar recordings viewed also included lessons in Anaphylaxis, Food Allergy Basics, and Diagnostics. Since its inception in November 2020, Food Allergy Academy usage has climbed to 71,982 with over 31,000 new users in 2022 alone.

Other learning highlights included the launch of the Food Allergy Fundamentals Curriculum based on the 2020 Food Allergy Primer authored by Dr. Tom Casale. This course is ACCME accredited through American Association of Asthma, Allergy and Immunology and provides 14.5 CE/CME credits for all types of medical professionals. Additionally, an updated version of STOP. LOOK. ASK. GO: Food Allergy Education curriculum for early childhood providers was launched in partnership with Northwestern University. Over 15,000 teachers and other educators participated in and completed this training. FARE’s Food Allergy webinar series with Food Allergy Counselor Tamara Hubbard also expanded to meet current need. The series now includes education and information on social-emotional health issues related to food allergy.

A premier FARE offering, the FARECheck program grew exponentially in 2022. FARECheck is an enhanced training and review program in food handling and safety practices to help keep food-allergic individuals safe and included when dining out while also helping food service establishments reduce the risk associated with accidental exposure to food allergens. In 2022, the FARECheck Food Allergy Training proudly achieved accreditation from the ANSI National Accreditation Board (ANAB), and expanded its certifications to notable universities, corporations, and even sports teams/venues. To date, 197 locations have reached FARECheck Silver status and 2 locations have reached FARECheck Gold status, in recognition of their adoption of--and adherence to--strict food allergy protocols.

Highlighting 2022, the Food Allergy Summit was held in-person for the first time in three years, bringing together people impacted by food allergies for three days of educational sessions, insightful discussions and meaningful connections. Held in Orlando, FL from September 23-25, the Summit resulted in impressive participation and statistics, with 563 registrants (including 72% “first time” attendees), 62 educations sessions, 63 speakers, and 17 exhibitors.
On a smaller scale, the virtual Food Service Summit held November 1-3, boasted 275 registrants (a 117% increase over 2021), with nine sessions over three days. Two awards went to Southern Methodist University and Auburn University.

A robust food allergy prevention awareness and education initiative is being planned for 2023, based in large measure on 2022 completed market research into current awareness and adoption of food allergy prevention (early introduction) guidelines with primary care clinicians. This survey included 250 each of pediatricians, family physicians, nurse practitioners and physician assistants and will serve as the strategic benchmark for food allergy prevention efforts in 2023 and beyond.

Quotes from the 2022 Food Allergy Summit

“As an allergy mom, I often feel alone in navigating the world of food allergies with my 5-year-old. It was incredibly inspiring and empowering to be around a group of people who understand my daily struggle.”

“It was incredible to meet people that walk in the same shoes, when sometimes it can feel so isolating. The practical advice and tips, along with the general encouragement was priceless.”

“I loved absolutely everything about the summit. I am extremely blessed to be a part of it.”

LET’S GET LOUD! THE IMPORTANCE OF ADVOCACY

FARE advocates have made a tremendous impact in 2022. By harnessing their collective voice and personal stories to influence public policy that supports the food allergy community, they have waged two successful appropriations efforts—securing $10 million in new federal investments for the food allergy community and nearly doubling (98.3% increase) the budget for the National Institute of Allergy and Infectious Diseases (NIAID) CoFAR (Consortium of Food Allergy Research) from $6.1 million to $12.1 million.

FARE, with the help of these advocates, led the development of a Food Allergy Collaborative submission toward the White House Conference on Hunger, Nutrition, and Health that resulted in two mentions of food allergy related to food labeling and research in the White House’s national strategy.

2022 saw the passage of four state and local laws supporting the food allergy community, specifically benefitting the 2.9 million food allergy families or more than 8% of America’s food allergy population in these states:

- **California**, Zacky’s Law
- **Missouri**, allowing school bus drivers and other school personnel to administer epinephrine auto-injectors
- **New York**, improving food allergy awareness at grocery stores and restaurants
- **Westchester County, NY**, restaurant training bill
In May 2022 FARE brought together more than 200 advocate voices to lobby on food allergy issues during the “Courage at Congress: Advocate for a Cure” virtual fly-in. As a result of these efforts, the Omnibus spending bill, S. 3799, the Prevent Pandemics Act, was passed into law and gives the FDA the power to extend the expiration date on certain medicines including epinephrine. FARE also added seven new members to the bipartisan Congressional Food Allergy Research Caucus in 2022, for a total of 16 leading into the 118th Session of Congress.

FARE worked diligently since May of 2022 with the Food and Drug Administration as well as Congressional supporters to ensure the proper implementation of the FASTER Act. When certain baking companies began to intentionally add sesame to previously sesame-free products, FARE took definitive action, engaging in dialogue and meetings with the American Bakers Association on behalf of the food allergy community. Through a special page on FARE’s website and strident efforts publicly and behind-the-scenes, FARE kept the food allergy community informed while raising awareness about this issue.

FARE could not have made such amazing progress on the legislative front without the support of the individuals and families using their voices to raise awareness of important issues impacting the food allergy community. This year, FARE recruited an additional 16,121 grassroots advocates, exceeding our goal of 5,000 by 222.4%. From making sure allergens such as sesame are properly labeled, to helping kids with food allergies stay safe in school, to increasing the money spent on research to find treatments and cures, food allergy advocates are the individuals responsible for true change.

FARE is committed to expanding access to patient care and impactful research for all those suffering from food allergies. Working to remedy inequities in food allergy management and care, FARE has prioritized health equity, diversity, and community engagement, and in 2022 broadened its commitment to improving access to patient care, support, and impactful research for all those living with food allergies.

Health Equity Statistics

Studies show that underserved communities of color are disproportionately impacted by food allergy. For example, among children on Medicaid, Black children are 7 percent more likely to develop food allergies than White children. Also, when compared to White children, Black and Hispanic children are twice as likely to have a severe food allergy reaction and to visit the emergency department. Additionally, Black children are two to three times more likely than White children to die from a severe allergic reaction to food. Yet despite these disparities in food allergy impacts, one analysis found that Black and Hispanic/Latino participants together made up only 4 percent of the total participants in food allergy immunotherapy clinical trials that reported racial demographic data.
In October 2022, FARE—along with other members of the Food Allergy Collaborative (an alliance of advocacy organizations and those living with food allergy)—published the highly anticipated **Voice of the Patient Report: Food Allergies**. The report stems from an externally-led patient-focused drug development meeting organized by the Food Allergy Collaborative that brought together more than 40 food allergy patients and caregivers who shared their insights with representatives of the U.S. Food and Drug Administration (FDA). Participant perspectives and public comments from the meeting compiled in the report are guiding FDA and pharmaceutical companies in efforts to develop effective therapies and improved policies. The report is available for download on FDA’s Condition-Specific Meeting Reports and Other Information Related to Patients’ Experience webpage.

**Community Access Program (CAP)**
Guided by volunteer advisory councils of caregivers, adults with food allergy, professionals, and community stakeholders, FARE’s **Community Access Program (CAP)** delivers health education, support, and care to under-resourced communities.

In 2022, FARE saw the largest expansion of its community partnerships, growing CAP to the Midwest—specifically Chicago’s Ward 15 and surrounding neighborhoods. FARE and its advisory councils collaborated with 28 community organizations, healthcare providers, schools, and others to offer 20 community-based education and awareness workshops in 2022.
Health Equity Survey Findings
Since the inception of its health equity portfolio in 2021, FARE staff have made six presentations at scientific and medical conferences, sharing information with researchers and healthcare providers about the impact of inadequate access to epinephrine and allergy-friendly food on the safety and security of food allergy patients and their families. FARE and its community and academic partners have also gathered insights from over 6,000 food allergy patients and caregivers who are more racially and ethnically diverse and more economically disadvantaged than most populations studied in food allergy research. These insights have led to collaboratively built, solution-driven programs that aim to improve outcomes for food allergy community members of color, as well as those facing economic hardship.

“In the survey FARE administered in the South Ward, we learned that 70% of families managing food allergy had used a food bank, and more than a quarter of families reported difficulty obtaining safe food due to the cost of the food. This indicates the critical need for food allergy education in our community, and the need to ensure that allergy-friendly foods are available and accessible for residents of all income levels.”

- Justine Asante, Director of Partnership Operations, South Ward Promise Neighborhood and FARE Community Access Program Partner

FARE Diversity Scholars
FARE is completing the inaugural year of the FARE Diversity Scholars Program. In partnership with National Medical Fellowships (NMF), the FARE Diversity Scholars Program provides one or two years of mentorship and $10,000 in annual financial support to graduate-level students historically underrepresented in medicine to engage in food allergy research and community engagement. In 2022, six FARE Diversity Scholars conducted research at exceptional food allergy centers within the FARE Clinical Network and networked with leading clinicians at the Food Allergy Summit. One third of the scholars have been selected to present their FARE funded work at the American Academy of Allergy, Asthma & Immunology 2023 Annual Meeting.
GIVING FOR THE FUTURE OF FOOD ALLERGY

Everything that FARE accomplished in 2022 could not have been possible without the generous support of our donors and corporate partners. From the donors who give $5 to the families who commit millions – each dollar goes to furthering FARE’s mission of improving the life and health of individuals with food allergies through transformative research, education, and advocacy.

The food allergy community has some of the world’s most generous individuals and families. For example, the Weiser Family’s $2M gift in support of new FARE CEO Sung Poblete helped push the needle on the SEED Study and other FARE initiatives. Adam Miller, FARE’s 10th Anniversary Co-Chair, pledged $1 million to further research in the food allergy space. The Naddisy Foundation and the Carter Family helped drive the Diagnostic Challenge forward with their impactful philanthropy and leadership. One of FARE’s Anonymous donors committed $1M to support the FARE Innovation Summit and FPIES research, and a $100,000 matching gift by OWYN and their CEO, Leigh Teuerstein, raised an additional $250,000 from over 650 members of the food allergy community. Additionally, fundraising efforts such as the Giving Tuesday Campaign that raised almost $60,000, happen throughout the year and generate much-needed funds to further FARE’s goals.

Other notable contributions by dedicated individuals include Dave Bunning’s tireless leadership as Chair, FARE Board of Directors from 2018-2022, and Denise and Dave Bunning’s incredible and visionary philanthropy to the food allergy community as a whole. Also, Kim and Alan Hartman continued their committed leadership and support in expanding the FARE Clinical Network, while the Olsen/Small family’s partnership with FARE and FASI on the neuroimmune study contributed greatly to FARE’s overall success.

On the corporate front, FARE’s relationships with our corporate partners are mutually beneficial and best serve our patient community while offering resources, information and access to our brand partners. From the core engagement opportunities to customized programming, FARE helps Corporate Partners measure the impact of their gift to support the food allergy community including targeted audience reach and engagement, targeted exposure of brand materials marks, logos and materials, affiliation with a trusted resource, and access to food allergy sufferers and statistics for feedback and research. These partners make both financial and in-kind contributions to help move forward FARE’s brand recognition and awareness.

In support of FARE’s 10th Anniversary, DBV Technologies contributed $250,000 and is the title corporate sponsor for all 10th anniversary activities. DBV CEO Daniel Tassé served as a keynote speaker at FARE’s Food Allergy Summit in Orlando in September 2022 and will serve as the co-chair of the upcoming FARE Gala in 2023.

The National Dairy Council (NDC), the nutrition research, education, and communications arm of Dairy Management Inc. generously committed $600,000 to the Start Eating Early Diet (SEED) Study, being conducted by the team at Northwestern University Feinberg School of Medicine. The SEED Study is instrumental to FARE’s food allergy prevention work, and NDC’s contributions will help support continued recruitment of participants, biospecimen sample storage and collection, and other study activities through 2026.

In addition to financial contributions, partners can make in-kind donations of their services, time and expertise, such as JP Morgan. They provided FARE resources to 25 wellness clinics, 14 daycare centers and featured FARE in their online employee newsletter in September and October to promote Back to School efforts and the Teal Pumpkin Project to raise awareness of FARE and food allergy issues.

In celebration of equity and inclusion for the Halloween holiday, CVS Pharmacy supported FARE’s 2022 Teal Pumpkin Project with digital and in-store educational activation and a gift of $120,000 to support FARE’s mission. Thanks to CVS, over 4,000 locations serving food allergy families with non-food trick-or-treat goodies, teal pumpkin decorations, and information about the importance of awareness were added to our Teal Pumpkin Project Map.
2022 DONORS

$5,000,000 +
Sunshine Charitable Foundation – Denise and Dave Bunning
Christine Olsen, MD and Robert Small

$2,500,000-$4,999,999
Anonymous
Hartman Family Foundation
The Weiser Family

$1,000,000-$2,499,999
Anonymous
1P Foundation
Helen and David Jaffe, and the Jaffe Family
Anna and Peter Kolchinsky
Naddisy Foundation, Inc.
Ira and Diana Riklis Family

$500,000 - $999,999
National Dairy Council/Dairy Management Inc.

$250,000-$499,999
DBV Technologies, Inc.
The Donald Levin Family Foundation
Nestlé Health Science
Cari and Michael J. Sacks

$100,000-$249,999
Anonymous
Aimmune Therapeutics
Jamie and David Baron
Laura and Jonathan Beinner
Hillary and Ben Carter
Clubhouse Capital Foundation - Beth and Bradley Berger
Compass Group
CVS Pharmacy
Leigh and Amy Feuerstein and OWYN
Rachel and Tim Gordon
Dr. Louise Matthews and Thomas Flickinger (Edward E. and Marie L. Matthews Foundation)

$5,000-$99,999
Applegate Farms
Linda and Bill Friend and The Harris Family Foundation
Gayden Family Foundation
Genentech, Inc.
Laura and Dan Gold
Wende Fox Lawson and Jim Lawson
National Peanut Board
Reckitt / Mead Johnson Nutrition
The Safe + Fair Food Company
YumEarth

$50,000-$99,999
Justine Stamen Arrillaga and John Arrillaga
Rachael and Robert Dedman
Hittman Family Foundation
Nutricia North America
Peter R. Schneider Family Foundation
PhRMA
Robert L. Rich
Thermo Fisher Scientific
$10,000-$24,999

Alladapt Immunotherapeutics, Inc.
Sharman and David Altshuler
Amir and Rosita Manocherian Family Foundation
Amy and Keith Barnett
Basquet
Beck Foundation and Emily Nolan
Boyle Family Foundation
C.A. Shea & Company, Inc.
Katie and David Geenberg
Josh and Tara Geise
Gale Gero
Antoinette and Michael Griffith
Christine and Timothy Johnson
JP Morgan Chase Foundation
Kaléo
The Karin and Dean Teglia Family Foundation
Mary Kriauciuunas
Shelby and Steve Lewis
Serena Liew
Ellen Liu
Scott and Laura Malkin
Merkel Foundation – Randy and Sandy Benz
Vicki and Dillard Jeffrey Moore
Neal and Sherrie Savage Family Foundation
Robert and Rebecca Nichols
O’Shea Family Foundation and Diane Alzapiedi
Cara Rooney Moore
Melissa and Matthew Rubel
Sifter
Tepas Family Foundation
That’s it. Nutrition
The Zalkin Family

$2,500-$9,999

Anonymous
ACAAI
Ajinomoto Cambrooke
Bruce Alexander
Allergy Scout
Allergy Therapeutics
American Academy of Allergy, Asthma & Immunology (AAAAI)
Robin and Philippe Amouyal
Janet and Peter Atwater
Auth Family Charity
Sophie and David Bacher
Rick Baer
Aimee and Michael Benz
BlackRock
Brickbottom Foundation
Kathryn and Peter Briden
Julie, Brian and Chad Burrow
Butlein Family Foundation
Kathryn and James Caissy
Chicago Wolves Charities
Chubb Charitable Foundation
Frank and Margaret Colone
Christine Creter
Kathleen Crockett
Dell Technologies
Niall Devitt
Diane Lynn Family Foundation
Sophie Dowling
Draydor Foundation
David and Cory Drewes
Pat Duffy

East Rock Capital
Every Body Eat (Whole and Free)
Douglas Fainelli
Robert and Pamela Fair
Darrel and Sandy Fry
Patrick Fuelling
Georgia Federation of Women’s Club
Jonathan and Adena Walker Goldberg
Anne Griswold
Grosch Family Giving Fund
Jodi and Adam Gruber
Danielle Hasso
Herbert O. Wolfe Foundation
H.L. Epstein Family Foundation, Inc.
Ben Hurlburt
Christopher and Maureen Hurst
ISEC, Inc.
JJJ Family Foundation
ISEC, Inc.
Chris and Marianne Jahn
Donald and Llewellyn Jensen
Jerome J and Ursula Choromanski Family Foundation
John A Rodger Jr Foundation Inc.
George Konn
LA-DO Industries
Ann Leal
Leone Family Foundation
Leslie C. and Leonard A. Shapiro Family Foundation
Luca + Danni
Magagna Family Foundation
Gray Mabry
Shonna Mayfield
Sarah McLellan
Amanda Mele
Joseph and Katherine Mele
Kristine and David Meyer
Megan Moreland Sherer
Natter Family Foundation
Oats in Coats
Partake Foods
Peg Becker Giving Foundation
Perfect Day
Kraig Peterson
Physicians Alliance of America Inc.
Pixie Lizzie
John Reaves
Katie and Ken Rogers
River Run Golf & Country Club and Laura & Jack Sock
Sheli and Burt Rosenberg
Amanda Sarracino
Shapiro/Schwartz Family Fund
Daniel Shaykevich
Singer Family Foundation
Linda Sink
Timothy Sprangers
Shelby Staples
Virginia Stoddard
Linda and John Totten
White Mountains Capital, LLC
Mike and Rita Wilson
BOARD MEMBERS

Board of Directors
- David Jaffe, Chair
- Alan Hartman, Vice Chair
- Milton L. Brown, MD, PhD, FNAI, Director
- David Bunning, Director
- Leigh Feuerstein, Director
- Dev Ganesan, Director
- Helen Jaffe, Ex-Officio
- Adam Miller, Ex-Officio
- Sung Poblete, RN, PhD, Chief Executive Officer
- Robert L. Rich, Director
- Mary Weiser, Director

Board of Governors
- Denise A. Bunning, Co-Chair
- Kim Hartman, Co-Chair
- Janet Atwater
- Jamie Baron
- Hillary and Ben Carter
- David A. Crown, PhD
- Rachel J. Gordon, MD, MPH
- John J. Hannan
- Rebecca Lainovic
- Julie and Paul Leff
- Don Levin
- Louise Matthews, MD
- Robert Nichols
- Christine Olsen, MD
- Cari and Michael J. Sacks
- Sara Trachte

Board of National Ambassadors
- Kaye W. Cole, PhD, Co-Chair
- Kimberley Yates, Co-Chair
- Jenny Andjelkovic
- Alisa Brodkowitz
- Jeffrey Burman
- Katie Gleenberg
- Tara and Josh Geise
- Andrew Gilman
- Pooja Goradia
- Antoinette and Michael Griffith
- Priscilla Hernandez
- Julie Karish
- Stacy Klein
- Sarah Krahnenbuhl
- Michael Lade
- Sharon Lamberton, MS, RN
- Laura Little Sock
- Wende Fox Lawson
- Shelby and Steve Lewis
- Alison Marquis
- Emily Nolan
- Noreen Okarter
- Katie Rogers
- Melissa and Matt Rubel
- Sandhya Sabhnani
- Stacey and Marc Saiontz
- Debbie Spano
- Karin Teglia

BOARD MEMBERS

LEADERS

Rising Leaders Committee
- Jack Griffith
- Kayla King
- Carly Klein
- Katie Klein
- Ashley Dinah Koranteng
- Matthew Marangiello
- Alexa Moss

Staff Leadership
- Elaine Gansz Bobo, Vice President, Communications
- Jennifer Bufford, Vice President of Clinical Operations
- Robert Earl, Vice President of Regulatory Affairs
- Craig Fontenot, Vice President, Institutional Advancement
- Jason Linde, Senior Vice President, Government & Community Affairs
- Deb Morrison, Chief Finance Officer
- Sung Poblete, Chief Executive Officer

LEADERS

Leaders
- Daniel Kadden, Co-Chair
- Carlo Steinman, Co-Chair
- Sarah Ackerman
- Bryan Bunning
- Lauren Byrne
- Jamie Carnavalla
- Kendra Chapman
- Jack Griffith
- Kayla King
- Carly Klein
- Katie Klein
- Ashley Dinah Koranteng
- Matthew Marangiello
- Alexa Moss

Leaders
- Daniel Kadden, Co-Chair
- Carlo Steinman, Co-Chair
- Sarah Ackerman
- Bryan Bunning
- Lauren Byrne
- Jamie Carnavalla
- Kendra Chapman
- Jack Griffith
- Kayla King
- Carly Klein
- Katie Klein
- Ashley Dinah Koranteng
- Matthew Marangiello
- Alexa Moss